Research Papers

25 of 259 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Roles of N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modifications in gynecologic cancers: mechanisms and therapeuti…
Chen J; Guo B; Liu X; Zhang J; Zhang J; Fang Y; Zhu S; Wei B; Cao Y; Zhan L.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside.
Liu Y; Wang Y; Sun S; Chen Z; Xiang S; Ding Z; Huang Z; Zhang B.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
RHO GTPase family in hepatocellular carcinoma.
Wang T; Rao D; Yu C; Sheng J; Luo Y; Xia L; Huang W.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Targeting the integrated stress response in hematologic malignancies.
Nwosu GO; Powell JA; Pitson SM.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolys…
Zhang Z; Zheng Y; Chen Y; Yin Y; Chen Y; Chen Q; Hou Y; Shen S; Lv M; Wang T.
Exp Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma.
Lin XH; Liu ZY; Zhang DY; Zhang S; Tang WQ; Li DP; Zhang F; Chen RX; Weng SQ; Xue RY; Dong L.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.
Wang X; Yang X; Yuan X; Wang W; Wang Y.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-s…
Hamamoto R; Koyama T; Kouno N; Yasuda T; Yui S; Sudo K; Hirata M; Sunami K; Kubo T; Takasawa K; Takahashi S; Machino H; Kobayashi K; Asada K; Komatsu M; Kaneko S; Yatabe Y; Yamamoto N.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
RNA binding proteins in MLL-rearranged leukemia.
Tran TM; Rao DS.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant productio…
Li R; Ke M; Qi M; Han Z; Cao Y; Deng Z; Qian J; Yang Y; Gu C.
Exp Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30<sup>+</su…
Zhang P; Yang X; Cao Y; Wang J; Zhou M; Chen L; Wei J; Mao Z; Wang D; Xiao Y; Zhu H; Zhang S; Zhang T; Zhang Y; Zhou J; Huang L.
Exp Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndrom…
Wu J; Zhang Y; Qin T; Xu Z; Qu S; Pan L; Li B; Jia Y; Li C; Wang H; Gao Q; Cai W; Gong J; Zhao S; Li F; Gale RP; Xiao Z.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastr…
Li SS; Zhai XH; Liu HL; Liu TZ; Cao TY; Chen DM; Xiao LX; Gan XQ; Cheng K; Hong WJ; Huang Y; Lian YF; Xiao J.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
p53 amyloid aggregation in cancer: function, mechanism, and therapy.
Li J; Guo M; Chen L; Chen Z; Fu Y; Chen Y.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution.
Chang L; Cui Z; Shi D; Chu Y; Wang B; Wan Y; Ma Q; Zhang R; Li H; Cheng X; Cheng T; Zhu X; Li C; Yuan W.
Exp Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis.
Wu Z; Gu D; Wang R; Zuo X; Zhu H; Wang L; Lu X; Xia Y; Qin S; Zhang W; Xu W; Fan L; Li J; Jin H.
Exp Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.
Oudaert I; Van der Vreken A; Maes A; De Bruyne E; De Veirman K; Vanderkerken K; Menu E.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Current insight into the regulation of PD-L1 in cancer.
Liu Z; Yu X; Xu L; Li Y; Zeng C.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin.
Yu S; Ren X; Li L.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells.
Hanel W; Lata P; Youssef Y; Tran H; Tsyba L; Sehgal L; Blaser BW; Huszar D; Helmig-Mason J; Zhang L; Schrock MS; Summers MK; Chan WK; Prouty A; Mundy-Bosse BL; Chen-Kiang S; Danilov AV; Maddocks K; Baiocchi RA; Alinari L.
Exp Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Code Funding Declared
Targeting metabolic reprogramming in chronic lymphocytic leukemia.
Nie Y; Yun X; Zhang Y; Wang X.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity.
Lv K; Hu B; Xu M; Wan L; Jin Z; Xu M; Du Y; Ma K; Lv Q; Xu Y; Lei L; Gong H; Liu H; Wu D; Liu Y.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Mutational landscape of chronic myelomonocytic leukemia in Chinese patients.
Nie Y; Shao L; Zhang H; He CK; Li H; Zou J; Chen L; Ji H; Tan H; Lin Y; Ru K.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors.
Xu Y; Ye H.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells.
Zhao H; Jiang Y; Lin F; Zhong M; Tan J; Zhou Y; Liu L; Li G; Deng M; Xu B.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared